Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

Rhea-AI Summary

Dyne Therapeutics, a clinical-stage company focused on muscle diseases, will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, at 8:00 a.m. ET. The event will provide insights into Dyne's innovative therapeutics for genetically driven diseases, including myotonic dystrophy, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. A live webcast will be available on the company's website, with a replay accessible for 90 days post-event.

News Market Reaction – DYN

-9.57%

-9.57% Session move

In the trading session that priced this news, DYN declined 9.57%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan’s 6^th Annual Genetic Medicines Conference being held in New York, NY on Tuesday, October 4, 2022 at 8:00 a.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne has a broad portfolio of programs for serious muscle diseases, including candidates for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203

FAQ

When is Dyne Therapeutics participating in the Genetic Medicines Conference?

Dyne Therapeutics will participate in the Genetic Medicines Conference on October 4, 2022, at 8:00 a.m. ET.

Where can I watch the Dyne Therapeutics conference presentation?

The presentation can be viewed live on Dyne Therapeutics' website, with a replay available for 90 days after the event.

What diseases is Dyne Therapeutics focusing on?

Dyne Therapeutics focuses on developing therapeutics for muscle diseases, including myotonic dystrophy, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.

What is the ticker symbol for Dyne Therapeutics?

The ticker symbol for Dyne Therapeutics is DYN.

What innovative platform does Dyne Therapeutics use?

Dyne Therapeutics uses its proprietary FORCE™ platform to develop oligonucleotide therapeutics targeting muscle tissue.